Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,586 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06625593 | A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 168 | BeOne MedicinesINDUSTRY | 4 | Jul 9, 2026 | clinicaltrials |
| NCT07692750 | IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 56 | Zhejiang Cancer HospitalOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04773951 | A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors | completed | Phase 1 | 47 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05142592 | Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 34 | Nanjing Immunophage Biotech Co., LtdINDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT05543330 | A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC | recruiting | Phase 1 / Phase 2 | 116 | Wuhan YZY Biopharma Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06115902 | A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer | completed | Phase 1 | 153 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06478212 | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma | active not recruiting | Phase 1 / Phase 2 | 51 | Institut de Recherches Internationales ServierOTHER | 11 | Jul 8, 2026 | clinicaltrials |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | terminated | Phase 1 | 47 | BeOne MedicinesINDUSTRY | 5 | Jul 8, 2026 | clinicaltrials |
| NCT06888830 | A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour | recruiting | Phase 1 / Phase 2 | 374 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07416695 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC | recruiting | Phase 1 | 138 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07567235 | Clinical Study of CFH Protein Via Ice Microneedles for Radiation-Induced Skin Fibrosis | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07689656 | A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05270200 | Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse | recruiting | Phase 1 / Phase 2 | 40 | Zhujiang HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05751486 | A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma | completed | Phase 1 | 64 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06571422 | Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors | active not recruiting | Phase 1 | 59 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 2 | Jul 7, 2026 | clinicaltrials |
| NCT06940401 | JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations | active not recruiting | Phase 1 / Phase 2 | 44 | Suzhou Junjing BioSciences Co., Ltd.INDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07686744 | Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma(NPVPP) | not yet recruiting | Phase 1 | 8 | Jian LinOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07687004 | Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification(AL-005) | not yet recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03491709 | A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC | completed | Phase 1 | 18 | Dragonboat Biopharmaceutical Company LimitedINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03908814 | Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors | completed | Phase 1 | 66 | Dragonboat Biopharmaceutical Company LimitedINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04077463 | A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer(Chrysalis-2) | active not recruiting | Phase 1 | 701 | Janssen Research & Development, LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT04739111 | An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor | completed | Phase 1 | 12 | Dragonboat Biopharmaceutical Company LimitedINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04898634 | A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer | active not recruiting | Phase 1 | 216 | Janssen Research & Development, LLCINDUSTRY | 6 | Jul 6, 2026 | clinicaltrials |
| NCT07538804 | A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 294 | Avistone Biotechnology Co., Ltd.INDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT07645222 | PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC | recruiting | Phase 1 | 396 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683403 | Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer | not yet recruiting | Phase 1 / Phase 2 | 138 | Fudan UniversityOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05489237 | First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | active not recruiting | Phase 1 | 276 | IDRX, Inc., a wholly owned subsidiary of GSK, LLCINDUSTRY | 11 | Jul 2, 2026 | clinicaltrials |
| NCT06001684 | Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors | completed | Phase 1 | 19 | Imbioray (Hangzhou) Biomedicine Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06022250 | The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor | active not recruiting | Phase 1 | 98 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06166836 | a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 140 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06234904 | Study of IBR733 Cell Injection in Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | Imbioray (Hangzhou) Biomedicine Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06464185 | A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 53 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06839105 | A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies | recruiting | Phase 1 | 214 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07073833 | The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma | recruiting | Phase 1 | 40 | Imbioray (Hangzhou) Biomedicine Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07473726 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 72 | Shanghai Henlius BiotechINDUSTRY | 2 | Jul 2, 2026 | clinicaltrials |
| NCT07647744 | To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer | recruiting | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07681141 | Clinical Study of 177Lu-JH040182 in Patients With FAP-Positive Malignancies | active not recruiting | Phase 1 | 3 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06179511 | Study of AZD9829 in CD123+ Hematological Malignancies | completed | Phase 1 / Phase 2 | 56 | AstraZenecaINDUSTRY | 10 | Jul 1, 2026 | clinicaltrials |
| NCT06209385 | A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors | completed | Phase 1 | 14 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07010120 | A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 29 | West China HospitalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07664150 | CW-301 FIH Study of CAN016 | recruiting | Phase 1 / Phase 2 | 90 | Canwell Biotech LimitedINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07677878 | Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL | recruiting | Phase 1 | 60 | Liping DouOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05170958 | A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 / Phase 2 | 396 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07009457 | A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer | active not recruiting | Phase 1 | 24 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07056777 | Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer | recruiting | Phase 1 / Phase 2 | 186 | Zhejiang Doer Biologics Co., Ltd.INDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07119996 | Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients | recruiting | Phase 1 | 12 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07244835 | A Study of DEG6498 in Participants With Solid Tumors | recruiting | Phase 1 | 100 | Degron Therapeutics Co.INDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials